ArticleCancer management and research2025
Combined Detection of Tumor Stem Cell Markers CD133 and OCT4 in Early Non-Small Cell Lung Cancer Screening and Prognostic Evaluation.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the expression of cancer stem cell (CSC) markers CD133 and OCT4 in early-stage non-small cell lung cancer (NSCLC), evaluate their diagnostic value in early screening, and analyze their prognostic significance. Methods: A retrospective study was conducted on 80 patients with early-stage NSCLC (stages I-IIA) and 40 healthy controls from January 2021 to December 2023. Expression levels of CD133 and OCT4 were assessed by immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR). Clinicopathological data were analyzed, and all patients were followed for 24 months to assess overall survival (OS). Diagnostic efficacy was evaluated by ROC analysis, and prognostic factors were identified by Cox regression. Results: CD133 and OCT4 were significantly upregulated in NSCLC tissues compared with adjacent normal tissues and healthy controls (P<0.001). High expression correlated with poor differentiation, larger tumor size (≥3 cm), lymph node metastasis, and stage IB-IIA (P<0.05). ROC analysis showed AUCs of 0.809 for CD133, 0.796 for OCT4, and 0.893 for their combination, with combined sensitivity of 88.7% and specificity of 82.5%. Patients with high expression of both markers had markedly reduced 2-year OS compared with low-expression cases (P<0.01). Multivariate Cox regression identified high CD133 expression (HR=2.45, 95% CI: 1.38-4.36, P=0.003), high OCT4 expression (HR=2.17, 95% CI: 1.22-3.86, P=0.007), poor differentiation (HR=1.91, P=0.021), tumor size ≥3 cm (HR=1.84, P=0.039), lymph node metastasis (HR=2.08, P=0.020), and stage IB-IIA (HR=2.22, P=0.016) as independent prognostic risk factors. Conclusion: CD133 and OCT4 are overexpressed in early-stage NSCLC and are associated with aggressive disease and poor prognosis. Combined detection provides superior diagnostic accuracy (AUC=0.893) compared to single markers and may serve as a valuable biomarker panel for early screening and risk stratification. These markers also have potential utility in guiding individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.